Neuprozyme Therapeutics ApS: Financial statements 2021
CVR: 40010106
Source: annual report 2021, Danish Business Authority
01/07/2020 – 30/06/2021
Neuprozyme Therapeutics ApS (CVR 40010106) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK 1,031,282 and a net result of DKK -289,040 compared with DKK -35,542 the year before. Equity in the 2021 report amounted to DKK -282,082.
- Gross Profit
- DKK 1,031,282
- Profit/Loss
- DKK -289,040
- Equity
- DKK -282,082
- Total Assets
- DKK 48,629
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | - | 1M | -289K | -282K | - |
| 2020 | - | -39K | -36K | 7K | 0 |
| 2019 | - | -8K | -8K | 43K | - |
| 2018 | - | - | 0 | 50K | - |
Official annual report
Find more companies like Neuprozyme Therapeutics ApS
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorAbout Neuprozyme Therapeutics ApS
Neuprozyme Therapeutics ApS is a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2018. The company is registered under the industry Fremstilling af andre organiske basiskemikalier. The management consists of John Pedersen. The board consists of John Pedersen and Lone Ballegaard Pedersen. The company is owned by LJP HOLDING ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -27,482 and a net result of DKK -25,574 compared with DKK -24,871 the year before. Equity in the 2025 report amounted to DKK 82,360.